X4 PHARMACEUTICALS, INC Increase (Decrease) in Accounts Receivable
X4 PHARMACEUTICALS, INC (XFOR) reported Increase (Decrease) in Accounts Receivable of $1.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $934.00K, a 46.86% increase year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $541.00K.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$318.00K, a 129.72% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$254.00K.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for fiscal 2025 was -$497.00K, a 146.45% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for fiscal 2024 was $1.07M.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $934.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.48M 10-Q · filed 2026-08-06 | $1.16M derived: sum of 3 quarters · filed 2026-08-06 | $903.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $541.00K 10-Q · filed 2026-05-06 | $223.00K derived: sum of 2 quarters · filed 2026-05-06 | -$31.00K derived: sum of 3 quarters · filed 2026-05-06 | $605.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$572.00K derived: sum of 2 quarters · filed 2026-03-17 | $64.00K derived: sum of 3 quarters · filed 2026-08-06 | -$497.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $382.00K derived: sum of 2 quarters · filed 2026-08-06 | -$179.00K 10-Q · filed 2025-11-05 | $891.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $75.00K 10-Q · filed 2026-08-06 | $1.15M derived: sum of 3 quarters · filed 2026-08-06 | $1.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$561.00K 10-Q · filed 2026-05-06 | $509.00K derived: sum of 2 quarters · filed 2026-05-06 | $509.00K derived: sum of 3 quarters · filed 2026-05-06 | $509.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.07M derived: sum of 2 quarters · filed 2026-03-17 | $1.07M derived: sum of 3 quarters · filed 2026-03-17 | $1.07M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-26 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-06 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |